Cargando…
Quality of life, long-term survivors and long-term outcome from the ABC-02 study
BACKGROUND: The ABC-02 (Advanced Biliary Tract Cancer) study established cisplatin and gemcitabine (CisGem) as the standard first-line chemotherapy for patients with locally advanced or metastatic biliary tract cancer (BTC). We examine quality of life (QoL), describe the long-term survivors and prov...
Autores principales: | Bridgewater, John, Lopes, Andre, Palmer, Daniel, Cunningham, David, Anthoney, Alan, Maraveyas, Anthony, Madhusudan, Srinivasan, Iveson, Tim, Valle, Juan, Wasan, Harpreet |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4984909/ https://www.ncbi.nlm.nih.gov/pubmed/27115567 http://dx.doi.org/10.1038/bjc.2016.64 |
Ejemplares similares
-
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial
por: Valle, Juan W, et al.
Publicado: (2015) -
Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial
por: Backen, Alison C., et al.
Publicado: (2018) -
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
por: Lamarca, Angela, et al.
Publicado: (2021) -
Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study – The UK ABC-01 Study
por: Valle, J W, et al.
Publicado: (2009) -
Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials
por: McNamara, Mairéad Geraldine, et al.
Publicado: (2017)